Recent Posts

Regulatory intelligence: Update on regenerative medicine advanced therapies designations May 14, 2019 - This article discusses the scope and purpose of the special designation for Regenerative Medicine Advanced Therapies (RMAT) created by the passage of the 21st Century Cures Act.  Click here to access the full article. Read More >
jCyte Presents Results of Clinical Testing in Retinitis Pigmentosa December 14, 2017 - Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa (RP). Presented by David S. Boyer, MD, at the annual Ophthalmology Innovation Summit in… Read More >
Where Our Retinitis Pigmentosa Therapy is Right Now July 17, 2017 - In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute for Regenerative Medicine (CIRM). In April, we announced our phase… Read More >